Search
EN

Bio-Shield 2019-Ncov Igg Immunoglobulin

Semi-quantitative ELISA test of 48 or 96 wells quantifying IgG antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens.
SKU: C1196

Register or Log In in order to request a quote

Register Login

Products specifications
TechnologyELISA
Sizes96 Tests
Semi-quantitative ELISA test of 48 or 96 wells quantifying IgG antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens.

GENERAL INFORMATION: Coronaviruses are enveloped, positive-sense and single-stranded RNA viruses with a nucleocapsid of helical symmetry and are composed of several proteins including the Spike (S), Envelope (E), Membrane (M) and Nucleocapsid (N) proteins. The S protein is very immunogenic with the Receptor Binding Domain (RBD) being the target of many neutralizing antibodies. The 2019 SARS-CoV-2 emerged in the Chinese province of Hubei (Wuhan) in December 2019 and has been declared a pandemic on 11 March 2020. This outbreak has spread rapidly, with millions of reported cases and thousands of deaths worldwide. Currently, there is no medication or vaccine available against infection with this new virus. Antibodies are produced by the immune system after an average of 7 days after infection. The Immunoglobulins M and A and G are produced in response of the infection and the Seroconversion for IgG and IgM occurs simultaneously or sequentially. Both IgG and IgM titers reach a plateau within 6 days after seroconversion. Within 19 days after symptom onset, all patients tested are positive for IgG against SARS-CoV-2. Serological testing may be helpful for the diagnosis of suspected patients with negative RT–PCR results (determining the number of cases of COVID-19) and for the identification of asymptomatic infections.

LATERAL FLOW KIT CHARACTERISTICS:
-Semi-quantitative ELISA test with single-break strip plate with 48 wells (6 strips) or 96 wells (12 strips)
-Clinical Diagnostic Sensitivity 97,33%, 73/75 (CI: 0.9079 to 0.9927), Clinical Diagnostic Specificity 100%, 91/91 (CI: 0.9595 to 1)
-Internal validation results: 97.43%, 76/78 (CI: 0.9112 to 0.9929) sensitivity & 99.85%, 666/667 (CI: 0.9916 to 0.9997). specificity
-Test time: 90 min
-Compatible with automated ELISA systems
-Shelf Life: 12 months | Storage 2-8 °C
Similar Products

Grs Viral Dna/Rna Purification Kit

Purification of DNA and/or RNA: for DNA and RNA from cell-free media (serum, plasma, body fluids and the supernatant from viral infected cell cultures)

Bio-Shield Surface Ag 2019-Ncov

The Bio-Shield Surface Ag 2019-nCov is an ELISA test for the measurement of SARS-CoV-2 Nucleocapsid Protein (NP) in swabs of common surfaces.
The test is intended for environmental swabbing of larger facilities & spaces and is adequate for up to 48 sample definitions at a time.

Viroreal® Kit Sars-Cov-2 & Sars

Detection of RNA of SARS-CoV strains including SARS-CoV-2 and SARS-like CoV without discriminating between strains.
Detection of the virus is responsible for the disease COVID-19 (corona virus disease 2019) and also detection of the new SARS-CoV-2 variant from the UK B1.1.7 (VOC-202012/01), the Delta variant and the variant from South Africa B.1.1.529.

ViroReal® Kit SARS Coronavirus & Influenza A/B

Detection of RNA of the nucleocapsid protein gene of coronavirus SARS-CoV-2, SARS-CoV and SARS-like CoV and influenza A/B virus

Rapid Test Surface Ag 2019-Ncov

The Rapid Surface Ag 2019-nCov is a rapid test for the detection of SARS-CoV-2 Nucleocapsid Protein Antigen (NP) in swabs of common surfaces, such as metal, plastic, glass, paper, and stainless steel. It is the first product for COVID-19 surface testing to utilize this innovative methodology.
The Rapid Surface Ag 2019-nCov is a valuable tool for several sectors enabling the companies to monitor and mitigate the spread of COVID-19 in their facilities and maintain a safe operating environment.